Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease, affecting approximatelyb25% of the global population. NAFLD ranges from simple steatosis to necroinflammation, fibrosis and cirrhosis. There are two types of NAFLD, and about 20% of patients with NAFLD progress to Non-alcoholic steatohepatitus (NASH). Patients with NASH often develop more serious liver conditions, such as fibrosis/cirrhosis of the liver and hepatocellular carcinoma (HCC)
As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your NAFLD or NASH study design, assuring high-quality data delivery and regulatory approval. Our network of laboratories offers services across the globe including anatomic pathology and biomarker delivery.